Medical Condition News

RSS

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

12 May 2010

Colorectal cancer screening rates much lower among African Americans: Study

Among African Americans, colorectal cancer is the third most common cause of cancer-related death. With the proper screening, it has a 90 percent cure rate, yet screening rates are much lower among this group than other ethnic groups.

12 May 2010

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEA-Leti today announced the launch of the TARGET-PDT project designed to increase the effectiveness of photodynamic therapy for treating cancer by developing a novel nano carrier-based approach.

12 May 2010

Anti-inflammatory drugs help block kidney destruction that occurs with hypertension: Researchers

Anti-inflammatory drugs appear to help block the rapid kidney destruction that can occur with hypertension, Medical College of Georgia researchers report.

12 May 2010

Minimum-wage employees more likely to be obese than those who earn higher wages: UC Davis study

A new UC Davis study has found that minimum-wage employees are more likely to be obese than those who earn higher wages, adding to growing evidence that being poor is a risk factor for unhealthy weight.

12 May 2010

Study shows relationship between built environment, SES and changes in BMI

People living in neighbourhoods where they perceived traffic made it unpleasant to walk were more likely to have a higher BMI than those who didn't, according to a new University of Alberta study looking at the relationship between the built environment, socio-economic status, and changes in body mass index over a six year period.

12 May 2010

Adult patients with sickle cell disease may develop cognitive problems: Study

Sickle cell disease may affect brain function in adults who have few or mild complications of the inherited blood disease, according to results of the first study to examine cognitive functioning in adults with sickle cell disease.

12 May 2010

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

If you have asthma or eczema, your hyper reactive immune system may lower your risk of some of the most common types of cancer, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology.

12 May 2010

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

IMBiotechnologies Ltd., a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration to market its lead product, Occlusin 500 Artificial Embolization Device in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours.

12 May 2010

Australian TGA approves Acetadote for treatment of paracetamol poisoning

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote® (acetylcysteine) Injection has been granted regulatory approval for marketing and sale in Australia. Acetadote, an injectable drug used to treat acetaminophen (paracetamol) overdose, was approved by the Therapeutic Goods Administration (TGA), the government agency responsible for regulating drugs and medical devices in Australia.

12 May 2010

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.

12 May 2010

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes: Researchers

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes who have preexisting gum disease.

12 May 2010

Compugen discovers CGEN-928 as antibody drug target for treatment of multiple myeloma

Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.

12 May 2010

Phakic IOLs safer than laser surgery for correcting moderate short-sightedness

A new type of procedure for correcting short-sightedness could be safer than laser eye surgery, according to a new Cochrane Systematic Review. The study also shows that patients prefer the new procedure, despite there being little difference between the two in terms of improving vision.

12 May 2010

Overtime workers at 60% higher risk of heart-related problems

Working overtime is bad for the heart according to results from a long-running study following more than 10,000 civil servants in London (UK): the Whitehall II study.

11 May 2010

Amorfix, Epitomics collaborate to develop high-affinity monoclonal antibodies against cancer targets

Amorfix Life Sciences and Epitomics, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Amorfix has identified several disease specific epitopes (DSEs) on misfolded proteins with their proprietary ProMIS(TM) computational platform discovery technology, which will be used by Epitomics to generate highly specific monoclonal antibodies (mAbs).

11 May 2010

Hothead Technologies, Shafer partner to develop normothermia monitoring and management system

Hothead Technologies has executed an agreement with Shafer Medical Devices, a Division of Shafer Enterprises, LLC to develop and distribute a medical application of the H.O.T.™ System that supports the Shafer Medical Devices Hypo/Hyperthermic Pad in managing normothermia in patients, during pre-op, surgery, and post op.

11 May 2010

Study reveals association between cardiac vagal activity and functional somatic symptoms

A study in the current issue of Psychotherapy and Psychosomatics outlines some novel insights between cardiac vagal activity [heart rate variability in the high-frequency band (HRV-HF)] and symptoms that do not find an organic explanation.

11 May 2010

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

When one of the country's foremost physicians—people like Dr. Andrew Weil—need someone to care for their friends and family dealing with cancer, the man they turn to is Keith Block, M.D. "I believe in Keith's program and would head to the Block Center if I were facing a diagnosis of cancer. It is where I have and will continue to send my friends and family," said Dr. Weil.

11 May 2010

Scancell signs worldwide licensing agreement with NIH for TRP-2 and gp100 melanoma antigens

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, is pleased to announce it has signed a worldwide non-exclusive licensing agreement with the National Institutes of Health ('NIH'), a division of the U.S. Department of Health and Human Services, for use of the melanoma antigens TRP-2 and gp100, key components of Scancell's lead ImmunoBody® vaccine for melanoma, SCIB1.

11 May 2010

Medical Condition News

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Colorectal cancer screening rates much lower among African Americans: Study

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

Anti-inflammatory drugs help block kidney destruction that occurs with hypertension: Researchers

Minimum-wage employees more likely to be obese than those who earn higher wages: UC Davis study

Study shows relationship between built environment, SES and changes in BMI

Adult patients with sickle cell disease may develop cognitive problems: Study

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

Australian TGA approves Acetadote for treatment of paracetamol poisoning

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes: Researchers

Compugen discovers CGEN-928 as antibody drug target for treatment of multiple myeloma

Phakic IOLs safer than laser surgery for correcting moderate short-sightedness

Overtime workers at 60% higher risk of heart-related problems

Amorfix, Epitomics collaborate to develop high-affinity monoclonal antibodies against cancer targets

Hothead Technologies, Shafer partner to develop normothermia monitoring and management system

Study reveals association between cardiac vagal activity and functional somatic symptoms

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

Scancell signs worldwide licensing agreement with NIH for TRP-2 and gp100 melanoma antigens

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News